Oncology · Prostate CancerOtherclinicalmid-term

miR-6833-3p Promotes Prostate Cancer Progression via NUMB-NOTCH Pathway Inhibition

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 6:30:13 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The discovery that miR-6833-3p drives prostate cancer progression through the NUMB-NOTCH pathway presents a significant opportunity for novel therapeutic interventions. This could reshape treatment strategies and enhance patient outcomes in oncology, particularly for prostate cancer. Regulatory context from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) supports the near-term read. Assessment grounded in 6 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (ClinicalTrials.gov), sub-indication match (prostate cancer); mechanism alignment (io ). In prostate cancer, 0 regulatory and 2 competitive items passed relevance filtering for NUMB. Developing therapies targeting miR-6833-3p could lead to a competitive advantage in the oncology market, potentially capturing significant market share from existing prostate cancer treatments.

Competitive Pressure

The most relevant competitive pressure comes from Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer (Humanexa Signals) — sub-indication match (prostate cancer). Secondary pressure from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer. This finding suggests that targeting miR-6833-3p could be a novel therapeutic strategy in prostate cancer, potentially impacting existing treatment paradigms.

Regulatory Outlook

Regulatory risk is concentrated around New therapies targeting this pathway may require regulatory scrutiny for approval, impacting timelines and compliance strategies for drug development..

Key Risks

Elevated medium regulatory exposure for NUMB could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.
Signal severity is high — leadership review is warranted.

Key Opportunities

Developing therapies targeting miR-6833-3p could lead to a competitive advantage in the oncology market, potentially capturing significant market share from existing prostate cancer treatments.
Developing therapies that target miR-6833-3p or the NUMB-NOTCH pathway to enhance treatment efficacy in prostate cancer.

What Would Change This Assessment

This becomes more urgent if Monitor developments in miR-6833-3p-targeted therapies and their clinical trials in prostate cancer.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Mechanism alignment (IO )
FDA document
View source
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pilot Study to Evaluate Targeted Physical Activity Among Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer
Humanexa Signalsmedium relevance
Sub-indication match (prostate cancer)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Sub-indication match (prostate cancer)
OTUD5-SLC7A11 Axis Identified as Novel Target in AML Progression
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.
PubMedhigh relevance
Sub-indication match (prostate cancer); Entity match (numb)
FDA document
View source
Retinol dehydrogenase 11 promotes prostate cancer progression through upregulation of tropomyosin receptor kinase A.
PubMedmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
Ubiquitination-anchored signature defines neuroendocrine prostate cancer: hub genes and single-cell ecosystem insights from integrated bioinformatics analysis of public transcriptomic datasets.
PubMedmedium relevance
Sub-indication match (prostate cancer)
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Thyroid cancer-derived exosomal SPP1 promotes tumor progression by driving macrophage M2 polarization through the CD44/JAK2/STAT3 signaling pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FTO-mediated m(6)A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

NUMB
prostate cancer therapies
NOTCH signaling pathway

Commercial impact

high

Developing therapies targeting miR-6833-3p could lead to a competitive advantage in the oncology market, potentially capturing significant market share from existing prostate cancer treatments.

Regulatory impact

medium

New therapies targeting this pathway may require regulatory scrutiny for approval, impacting timelines and compliance strategies for drug development.

What to watch

Monitor developments in miR-6833-3p-targeted therapies and their clinical trials in prostate cancer.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.